Latest Period
Q1 2026
Security Snapshot
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) Institutional Ownership
CUSIP: 22663K107
13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026
Institutions Reporting
233
Shares (Excl. Options)
120,774,860
Price
$36.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- CRNX on Nasdaq
- Shares outstanding
- 105,000,216
- Price per share
- $41.00
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 120,774,860
- Total reported value
- $4,384,688,367
- % of total 13F portfolios
- 0%
- Share change
- +9,122,996
- Value change
- +$275,110,601
- Number of holders
- 233
- Price from insider filings
- $41.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK is tracked under CUSIP 22663K107.
- 233 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 239 to 233 between Q4 2025 and Q1 2026.
- Reported value moved from $5,195,621,593 to $4,384,688,367.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 233 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 22663K107?
CUSIP 22663K107 identifies CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22663K107:
Significant Owners of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +46% | $466,033,211 | +$144,432,819 | 13,957,269 | +45% | FMR LLC | 31 Mar 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.8% | -12% | $321,720,126 | -$8,865,599 | 8,157,204 | -2.7% | Wellington Management Group LLP | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 8.5% | +42% | $373,521,762 | +$111,673,450 | 8,024,098 | +43% | Dapice Joshua J. | 31 Dec 2025 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.1% | $252,255,164 | 6,395,922 | DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $197,604,263 | 5,440,646 | Vanguard Capital Management | 31 Mar 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | $211,201,634 | 5,355,011 | T. Rowe Price Associates, Inc. | 31 Mar 2026 |
As of 31 Mar 2026, 233 institutional investors reported holding 120,774,860 shares of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX). This represents 115% of the company’s total 105,000,216 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 15,759,799 | +10% | 0.03% | $572,395,895 |
| BlackRock, Inc. | 8.1% | 8,478,815 | +6.1% | 0.01% | $307,950,573 |
| FARALLON CAPITAL MANAGEMENT LLC | 7.9% | 8,338,098 | +20% | 2% | $302,839,719 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.8% | 8,157,204 | +1.5% | 0.06% | $296,269,650 |
| Driehaus Capital Management LLC | 6.1% | 6,395,922 | +0.13% | 1.7% | $232,299,887 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | 5,355,496 | +2.5% | 0.02% | $194,513,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 4,673,935 | 0% | 0% | $169,757,319 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 4,638,511 | 0% | 0.01% | $168,470,720 |
| JANUS HENDERSON GROUP PLC | 4.3% | 4,520,251 | +1.8% | 0.08% | $164,227,195 |
| EcoR1 Capital, LLC | 4.1% | 4,288,120 | 0% | 6.7% | $155,744,518 |
| Bellevue Group AG | 3.1% | 3,280,000 | +81088% | 2.8% | $119,129,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,480,763 | +11% | 0.01% | $90,119,429 |
| STATE STREET CORP | 2.3% | 2,403,046 | +11% | 0% | $87,278,631 |
| BAKER BROS. ADVISORS LP | 2.2% | 2,351,465 | +43% | 0.49% | $85,405,209 |
| T. Rowe Price Investment Management, Inc. | 1.8% | 1,940,622 | +3182% | 0.05% | $70,484,000 |
| Siren, L.L.C. | 1.8% | 1,903,636 | +26% | 1.9% | $69,140,060 |
| Pictet Asset Management Holding SA | 1.8% | 1,884,281 | +21% | 0.07% | $68,204,218 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.6% | 1,716,445 | +29% | 0.07% | $62,341,282 |
| GW&K Investment Management, LLC | 1.5% | 1,618,686 | +9.6% | 0.52% | $58,791,000 |
| NOVO HOLDINGS A/S | 1.5% | 1,550,000 | -4.6% | 4.6% | $56,296,000 |
| RTW INVESTMENTS, LP | 1.4% | 1,451,326 | +7.4% | 0.52% | $52,712,160 |
| JPMORGAN CHASE & CO | 1.3% | 1,324,668 | +15% | 0% | $45,396,372 |
| First Light Asset Management, LLC | 1% | 1,089,670 | -8.8% | 3.5% | $39,576,814 |
| AMERICAN CENTURY COMPANIES INC | 1% | 1,052,858 | -1.5% | 0.02% | $38,239,852 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0.99% | 1,043,879 | 1% | $37,913,685 |
Institutional Holders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 120,774,860 | $4,384,688,367 | +$275,110,601 | $36.32 | 233 |
| 2025 Q4 | 111,610,559 | $5,195,621,593 | +$186,370,978 | $46.55 | 239 |
| 2025 Q3 | 107,709,232 | $4,486,288,734 | +$149,976,766 | $41.65 | 225 |
| 2025 Q2 | 104,559,713 | $3,007,383,972 | +$75,026,414 | $28.76 | 220 |
| 2025 Q1 | 101,790,412 | $3,418,305,905 | +$9,856,311 | $33.54 | 225 |
| 2024 Q4 | 99,690,161 | $5,097,004,672 | +$758,098,969 | $51.13 | 245 |
| 2024 Q3 | 84,525,573 | $4,321,960,073 | +$33,724,194 | $51.10 | 233 |
| 2024 Q2 | 82,487,807 | $3,694,594,767 | +$92,152,096 | $44.79 | 232 |
| 2024 Q1 | 80,384,076 | $3,762,661,947 | +$486,785,470 | $46.81 | 201 |
| 2023 Q4 | 70,656,199 | $2,513,959,167 | +$68,274,571 | $35.58 | 180 |
| 2023 Q3 | 68,535,017 | $2,038,114,354 | +$440,832,585 | $29.74 | 171 |
| 2023 Q2 | 54,057,835 | $974,084,774 | -$11,795,159 | $18.02 | 138 |
| 2023 Q1 | 55,062,782 | $884,310,368 | +$2,280,401 | $16.06 | 127 |
| 2022 Q4 | 54,817,398 | $1,003,122,430 | -$14,306,281 | $18.30 | 121 |
| 2022 Q3 | 51,456,378 | $1,010,816,996 | +$16,147,822 | $19.64 | 118 |
| 2022 Q2 | 50,645,843 | $944,532,132 | +$94,595,270 | $18.65 | 109 |
| 2022 Q1 | 45,482,453 | $997,426,956 | -$15,117,112 | $21.95 | 114 |
| 2021 Q4 | 44,273,322 | $1,256,550,441 | +$251,517,738 | $28.41 | 114 |
| 2021 Q3 | 33,632,624 | $708,150,662 | +$17,177,215 | $21.05 | 91 |
| 2021 Q2 | 32,726,853 | $616,933,642 | +$42,446,903 | $18.85 | 81 |
| 2021 Q1 | 30,730,499 | $465,273,247 | +$5,520,857 | $15.28 | 78 |
| 2020 Q4 | 30,426,213 | $429,299,885 | -$4,592,533 | $14.11 | 84 |
| 2020 Q3 | 30,337,604 | $475,397,972 | -$19,900,117 | $15.67 | 70 |
| 2020 Q2 | 31,451,376 | $546,085,663 | +$188,712,886 | $17.52 | 79 |
| 2020 Q1 | 20,679,487 | $303,862,789 | +$45,411,611 | $14.70 | 55 |
| 2019 Q4 | 17,526,211 | $439,727,847 | -$5,476,519 | $25.09 | 58 |
| 2019 Q3 | 15,234,699 | $229,128,583 | -$94,271,503 | $15.04 | 60 |
| 2019 Q2 | 18,931,321 | $473,283,223 | +$31,131,935 | $25.00 | 63 |
| 2019 Q1 | 17,737,322 | $403,697,060 | +$20,738,652 | $22.76 | 62 |
| 2018 Q4 | 16,786,897 | $503,433,000 | +$19,006,654 | $29.99 | 50 |
| 2018 Q3 | 16,164,902 | $463,124,000 | +$463,124,002 | $28.65 | 49 |